Proteome Sciences plc
(the "Company" or the "Group")
Option Awards
Proteome Sciences plc (AIM:PRM) announces the award of 18,160,000 nominal cost options ("Options") over ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") to certain executive directors on 3 April 2017 (the "Award") as detailed below. The Options represent 6.17% of the current issued share capital of the Company and lapse on 3 April 2027 ("Lapse Date").
Director |
Current options Held |
New Unapproved Options |
New EMI Options |
Total Options Held |
Percentage of Issued Share Capital |
Vesting Date |
Jeremy Haigh |
Nil |
4,000,000 |
5,000,000 |
9,000,000 |
3.1% |
01 June 2019 |
Ian Pike |
165,583 |
Nil |
3,750,000 |
3,915,583 |
1.3% |
03 April 2020 |
Richard Dennis |
Nil |
Nil |
3,250,000 |
3,250,000 |
1.1% |
03 April 2020 |
Geoff Ellis |
300,000 |
2,160,000 |
Nil |
2,460,000 |
0.8% |
03 April 2020 |
TOTAL |
465,583 |
6,160,000 |
12,000,000 |
18,625,583 |
|
|
The Options will vest subject to the holders remaining employed until the vesting date and the satisfaction of the following performance requirements ("Performance Criteria") relating to the growth in the Company's share price, as quoted on the London Stock Exchange:
i. One third of the total Options awarded will vest if the Company's closing share price over a 5-day period attains 7p at any time after the Vesting Date but before the Lapse Date (the "Exercise Period");
ii. A further one third of the total Options awarded will vest if the Company's closing share price over a 5-day period attains 9p at any time during the Exercise Period; and
iii. The final one third of the total Options awarded will vest if the Company's closing share price over a 5-day period attains 11p at any time during the Exercise Period.
Once the Options have vested in accordance with the Performance Criteria, participants can exercise their Options at any time during the period commencing from the Vesting Date and ending on the Lapse Date.
Following the Award, the Company now has 19,526,548 options over Ordinary Shares outstanding representing 6.63% of the current issued share capital of the Company.
For further information: |
|
Proteome Sciences plc Dr Jeremy Haigh, Chief Executive Officer Dr Ian Pike, Chief Scientific Officer Geoff Ellis, Finance Director |
Tel: +44 (0)1932 865065 |
finnCap Limited (Nominated Adviser/Broker) Geoff Nash/James Thompson Tony Quirke (Broking) |
Tel: +44 (0) 207 220 0500 |
IFC Advisory (Financial PR and IR) Tim Metcalfe/Graham Herring/Miles Nolan |
Tel: +44 (0) 203 053 8761 |
|
|
|
Notes for editors:
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.
1. |
Details of the person discharging managerial responsibilities / person closely associated |
a) |
Name |
Jeremy Haigh |
2. |
Reason for the Notification |
a) |
Position/status |
Chief Executive Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Proteome Sciences plc |
b) |
LEI |
n/a |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the Financial instrument, type of instrument |
Options over Ordinary Shares of 1p each |
Identification code |
GB0003104196 |
b) |
Nature of the transaction |
Award of options |
c) |
Price(s) and volume(s) |
4,000,000 Unapproved Options 5,000,000 EMI Options |
d) |
Aggregated information: - Aggregated volume - Price |
9,000,000 Options over Ordinary Shares of 1p each |
e) |
Date of the transaction |
3 April 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities / person closely associated |
a) |
Name |
Ian Pike |
2. |
Reason for the Notification |
a) |
Position/status |
Chief Scientific Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Proteome Sciences plc |
b) |
LEI |
n/a |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the Financial instrument, type of instrument |
Options over Ordinary Shares of 1p each |
Identification code |
GB0003104196 |
b) |
Nature of the transaction |
Award of Options |
c) |
Price(s) and volume(s) |
3,750,000 EMI Options |
d) |
Aggregated information: · Aggregated volume · Price |
3,750,000 Options over Ordinary Shares of 1p each |
e) |
Date of the transaction |
3 April 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities / person closely associated |
a) |
Name |
Richard Dennis |
2. |
Reason for the Notification |
a) |
Position/status |
Chief Commercial Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Proteome Sciences plc |
b) |
LEI |
n/a |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the Financial instrument, type of instrument |
Options over Ordinary Shares of 1p each |
Identification code |
GB0003104196 |
b) |
Nature of the transaction |
Award of Options |
c) |
Price(s) and volume(s) |
3,250,000 EMI Options |
d) |
Aggregated information: · Aggregated volume · Price |
3,250,000 Options over Ordinary Shares of 1p each |
e) |
Date of the transaction |
3 April 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities / person closely associated |
a) |
Name |
Geoff Ellis |
2. |
Reason for the Notification |
a) |
Position/status |
Finance Director |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Proteome Sciences plc |
b) |
LEI |
n/a |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 1p each |
Identification code |
GB0003104196 |
b) |
Nature of the transaction |
Award of Options |
c) |
Price(s) and volume(s) |
2,160,000 Unapproved Options |
d) |
Aggregated information: · Aggregated volume · Price |
2,160,000 Options over Ordinary Shares of 1p each |
e) |
Date of the transaction |
3 April 2017 |
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
